Pain Management for Adult Burn Patients
For adults with burn-related pain and no contraindications, implement multimodal analgesia combining scheduled opioids (titrated intravenously initially, then transitioned to oral), acetaminophen, NSAIDs, and ketamine, with all medications titrated using validated pain assessment scales.
Core Pharmacological Strategy
The foundation of burn pain management requires a multimodal approach that has been shown to reduce opioid requirements while maintaining effective pain control 1, 2. This is critical because burn injuries trigger inflammation, hypermetabolism, and capillary leakage that alter drug pharmacokinetics 3.
Initial Acute Phase Management
Opioid Therapy:
- Start with intravenous opioids titrated as small boluses against effect 4
- Hydromorphone is the most frequently used agent, particularly for larger burns 5
- Consider patient-controlled analgesia (PCA) or continuous infusion for background pain 4
- Transition to oral opioids (oxycodone, hydromorphone) as patient stabilizes
Non-Opioid Analgesics:
- Acetaminophen: 1g every 4-6 hours (maximum 4g/day) as first-line scheduled medication 6, 1
- NSAIDs (ibuprofen 400mg every 6 hours, maximum 3200mg/day): particularly effective for inflammatory burn pain 6, 7
Ketamine:
- Titrated intravenous ketamine should be combined with other analgesics for severe burn pain 3
- Particularly effective for procedural pain and can limit morphine consumption 3
- Implementation of ketamine in multimodal protocols has shown significant benefit 1
Pain Type Differentiation
Background Pain:
- Managed with scheduled multimodal regimen (opioids + acetaminophen + NSAIDs)
- Continuous or PCA opioid delivery 4
Procedural Pain (dressing changes, debridement):
- Increase baseline opioid dose
- Add short-acting opioids (fentanyl) or ketamine boluses
- Consider inhaled nitrous oxide when IV access limited 3
- For highly painful procedures, general anesthesia is appropriate 3
Evidence-Based Outcomes
Recent implementation studies demonstrate that structured multimodal protocols significantly reduce opioid consumption. One 2025 study showed median cumulative morphine milligram equivalents decreased from 172 to 97 (p=0.042) after implementing a multimodal order set, without worsening pain scores 1. The protocol increased scheduled acetaminophen use from 62.5% to 95.2%, ibuprofen from 31.3% to 42.9%, and ketamine from 14.1% to 28.6% 1.
Burn Severity Considerations
Larger Burns (>40% TBSA):
- Require significantly higher opioid doses that persist longer 5
- At day 25, patients with >40% TBSA required 451±980 MME versus 237±388 MME for moderate burns (p=0.023) 5
- Hydromorphone use increases proportionally with burn severity 5
Smaller Burns (<20% TBSA in adults, <10% in children):
- Consider cooling the burn (if no shock present) to limit pain and burn deepening 3
Pain Assessment Requirements
Mandatory monitoring:
- Use validated numerical rating scales (NRS) or visual analog scales
- Assess pain regularly and document using standardized tools 3, 2
- Titrate all medications based on these objective measurements 3
Non-Pharmacological Adjuncts
When patient is stable and appropriate:
- Virtual reality or hypnosis for dressing changes 3
- Cooling of limited burned surfaces (<20% TBSA adults, <10% children) 3
- Cognitive-behavioral techniques, distraction, relaxation 4
Critical Pitfalls to Avoid
- Underdosing opioids due to fear of addiction—when used for acute burn pain, addiction is rarely a problem 7
- Using NSAIDs without monitoring: Check baseline and q3 month BP, BUN, creatinine, LFTs, CBC, and fecal occult blood 7
- Discontinuing NSAIDs too late: Stop if BUN/creatinine doubles, LFTs increase >3x normal, hypertension develops, or GI bleeding occurs 7
- Single-agent therapy: Multimodal regimens demonstrate superior pain stability compared to opioid-only or non-opioid-only approaches 5
- Inadequate procedural pain planning: Procedural pain requires different, more aggressive interventions than background pain 4